Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
Constantin TA, Varela-Carver A, Greenland KK, de Almeida GS, Olden E, Penfold L, Ang S, Ormrod A, Leach DA, Lai CF, Ainscow EK, Bahl AK, Carling D, Fuchter MJ, Ali S, Bevan CL.
Constantin TA, et al. Among authors: fuchter mj.
Br J Cancer. 2024 Mar;130(5):892. doi: 10.1038/s41416-024-02606-w.
Br J Cancer. 2024.
PMID: 38355841
Free PMC article.
No abstract available.